Advanced searches left 3/3

Metastatic Neuroendocrine Tumors - Europe PMC

Summarized by Plex Scholar
Last Updated: 20 May 2022

* If you want to update the article please login/register

Prognostic Nomogram Based on the Metastatic Lymph Node Ratio for T 1-4 N 0-1 M 0 Pancreatic Neuroendocrine Tumors After Surgery.

aims of this research The objective of this study was to investigate the clinical significance of the pancreatic neuroendocrine tumor subgroup of patients with pancreatic neuroendocrine tumors, as well as the ability to design and validate nomograms to predict 5-, 7-, and 10-year survival rates for pNETs after surgical resection. Methods The Surveillance, Epidemiology, and End Results database pulled together demographics and clinicopathological data of T 1-4 N 0-1 M 0 pNET patients between 2004 and 2018 were extracted from the Surveillance, Epidemiology, and End Results database, along with the End Results database. In the training group, a Cox regression model was used to obtain independent prognostic information in order to create nomograms for predicting OS and CSS. The nomograms had a higher success than the American Joint Committee on Cancer TNM staging equipment, according to DCA. Patients with a higher risk of infection had a poor prognosis, according to risk stratification. After surgery, the nomograms we created can help predict long-term survival for pNETs.

Source link: https://europepmc.org/article/MED/35574346


Metastatic Neuroendocrine Tumors to Parotid Gland: Where Do They Come From?

Metastasis to parotid gland is the most common skin cancer of the head and neck region. About 29% of parotid neoplasms were malignant, with 70 cases of parotid primary malignant tumors and 50 cases of metastases to parotid glands. The most common primaries were poorly differentiated neuroendocrine carcinoma of lung, with 4 cases of small cell carcinoma and one case of large cell neuroendocrine carcinoma. Merkel cell carcinoma, with one case of direct invasion from overlying skin, was the second most common secondary tumor. Metastatic neuroendocrine carcinomas to the parotid gland account for around 22% of all metastatic tumors to the organ, according to our results. Metastatic neuroendocrine carcinoma is not unprecedented to appear as the first sign of systemic clinical manifestation. Merkel cell carcinoma is the second most common disease that metastasizes to parotid, after medullary carcinoma of the thyroid.

Source link: https://europepmc.org/article/MED/35466730


Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.

In France, pancreatic neuroendocrine tumors were diagnosed in 2011 and 2012, respectively. Sunitinib and everolimus' effectiveness was determined by an observational study to compare traditional pNET treatments of chemotherapies and somatostatin analogues that had been previously only approved by the health authorities. The OPALINE study investigated the safety, disease progression, and tolerance of everolimus and sunitinib. Patients in seventy-nine were referred to at least one targeted therapy during their health care journey. During the follow-up showing the safe treatment tolerability over time, most patients receiving TTs did not change their dose during the follow-up. During this research, no new safety alert for everolimus and sunitinib was issued. Given their high tolerance and positive impact on estimated OS, the two TTs have a major role to play in the care pathway for patients with pNETs.

Source link: https://europepmc.org/article/MED/35419649


Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.

In Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors, this phase I/II was conducted to determine streptozocin's effectiveness, safety, and pharmacokinetics. Both patients were given up to four cycles of intravenous STZ at 500 mg/m2 once daily for five days in a row, or 1000-1500 mg/m2 once a week for six weeks. No patients had complete response; partial response in two, stable disease in 17; non-complete response/non-protergic disease in 2, non-evaluable disease in 2, and just one had non-evaluable disease. However, no adverse events were recorded in any of 22 patients, with 17 grade 3 adverse events in 11 patients; however, the best overall reaction in each patient showed that the disease control rate was 100%. STZ may be a useful treatment for Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.

Source link: https://europepmc.org/article/MED/35411926


Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor.

Pancreatic neuroendocrine tumors are a common disorder. In randomized trials, an ongoing debate has arisened over the role of surgery in the metastatic setting, as dedicated systemic therapies have appeared recently and demonstrated success. If the tumor has a favorable prognosis, liver transplantation is a viable option for advanced pNETs, as shown by a low to moderate proliferation index today. In a multidisciplinary tumor board, the most effective treatment plan for an individual patient should be considered.

Source link: https://europepmc.org/article/MED/35326628

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions